Company Overview - The company, Vaimo Biotechnology (Zhejiang) Co., Ltd., focuses on the ophthalmology sector and aims to become a global leader in innovative ophthalmic therapies [4] - Established in 2016, the company has developed a competitive and differentiated product pipeline addressing various ophthalmic indications with significant unmet clinical needs [4] Core Products - VVN461 (High Dose) is a novel dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), currently undergoing Phase III clinical trials in China for non-infectious anterior uveitis (NIAU) [4][6] - VVN001 is a second-generation LFA-1 antagonist designed for treating dry eye disease (DED), with ongoing Phase III clinical trials in China [4][9] Clinical Development - VVN461 has shown comparable anti-inflammatory efficacy to corticosteroids in head-to-head Phase II trials, with a breakthrough therapy designation granted by the National Medical Products Administration (NMPA) [7] - VVN001 demonstrated higher efficacy and safety compared to the standard treatment cyclosporine A (CsA) in clinical trials, improving patient experience and compliance [10] Financial Information - For the nine months ending September 30, 2024, the company reported other income and gains of approximately RMB 8.572 million, with research and development expenses of about RMB 128.261 million [11] - The company incurred losses of approximately RMB 201.535 million for the fiscal year ending 2024 [12] Industry Overview - The global ophthalmic drug market is estimated to reach USD 41.6 billion in 2024, with a projected compound annual growth rate (CAGR) of 2.8% from 2024 to 2029, driven by an aging population and increasing prevalence of eye diseases [13] - The Chinese ophthalmic drug market is expected to grow from USD 2.7 billion in 2020 to USD 4.1 billion in 2024, with a CAGR of 10.8% [16]

Company Overview - The company, established in 2016, focuses on the ophthalmology sector and aims to become a global leader in innovative ophthalmic therapies [5] - It has developed a competitive and differentiated product pipeline addressing various ophthalmic indications with significant unmet clinical needs [5] Core Products - VVN461 (high dose) is a novel dual-target inhibitor of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), currently undergoing Phase III clinical trials in China for non-infectious anterior uveitis (NIAU) [5][6][8] - VVN001 is a second-generation LFA-1 antagonist designed for treating dry eye disease (DED), with ongoing Phase III clinical trials in China [10][11] Clinical Trials and Approvals - VVN461 received IND approval from the National Medical Products Administration (NMPA) in January 2023 and has shown comparable anti-inflammatory efficacy to corticosteroids in clinical trials [8][7] - VVN001 has also received IND approval and has demonstrated higher efficacy and safety compared to the standard treatment, cyclosporine A [11][10] Financial Information - The company reported other income and gains of RMB 8.572 million and RMB 3.444 million for the nine months ending September 30 in 2024 and 2025, respectively [12][14] - Research and development expenses were approximately RMB 128.261 million and RMB 65.178 million for the same periods, with annual losses of RMB 201.535 million and RMB 131.495 million [13][14] Industry Overview - The global ophthalmic drug market is estimated to reach USD 41.6 billion in 2024, with a projected CAGR of 2.8% from 2024 to 2029, driven by an aging population and increasing prevalence of eye diseases [15][18] - The Chinese ophthalmic drug market is expected to grow from USD 2.7 billion in 2020 to USD 4.1 billion in 2024, with a CAGR of 10.8%, and further growth anticipated to USD 6.6 billion by 2029 [18]

智通财经APP获悉，亿胜生物科技(01061)午后涨近9%，截至发稿，涨5.83%，报4.36港元，成交额 525.76万港元。 值得注意的是，公司近期宣布，全资附属Majeton与Osteopore订立独家分销协议。Osteopore在3D打印仿 生且可生物吸收植入物方面是全球领军企业。与Osteopore的合作为集团在口腔市场树立了里程碑，并 扩展了集团牙科、正畸及颌面解决方案的产品线，将共同助力集团在中国市场追求可持续增长。 消息面上，亿胜生物科技近期宣布，集团将参展于2月5日至8日在中国香港会议展览中心举办的2026年 亚太眼科学会年会(APAO 2026)。集团将重点展示EB12-20145P(贝伐珠单抗)、单剂量贝复舒滴眼液两款 核心产品。其中，EB12-20145P持续展现强劲的临床开发势头。该项目已入选大会海报展示环节，届时 将向国际眼科界呈现临床进展及研发洞见。 ...

150 週20 128.42 120-1 118.85 44.99 90 88-25 60 59,18 2793 45.87 30 0 2020-12-37 ' 2027-12-37 ' 2022-12-37 1 022-06-30 5-12-37 -1-06-30 2n- -○- 公司 -○- 行业均值 100 ହ 90 80 _71o84 70 68:68 69p 65-21 60 50 45,7 40 30 27875 20 10 0 2027-12-37 1 2020-12-37 ' 2022-72-37 1 1-06-30 2-06-30 5-12-37 2n- ） 中证智能财讯兴齐眼药（300573）1月22日晚间披露2025年度业绩预告，预计2025年归母净利润6.62亿元至7.49亿元，同比增长95.82%-121.56%；扣非净利润 预计6.62亿元至7.49亿元，同比增长90.48%-115.51%。以1月22日收盘价计算，兴齐眼药目前市盈率（TTM）约为25.78倍-29.17倍，市净率（LF）约10.29 倍，市销率（TTM）约8.02倍。 以本次披露业绩预告均值计算，公司近年市盈率（ ...

【财华社讯】截至发稿，拨康视云-B(02592.HK)涨9.75%，报8.78港元。消息面上，该公司午间公布， 公司于美国加利福尼亚州注册成立的全资附属公司Cloudbreak USA，排定于2025年12月10日与美国食品 及药物管理局正式举行第2期临床试验后会议，该会议涉及集团临床阶段候选药物CBT-004。 本文源自：财华网 CBT-004是一种潜在的同类首创眼科药物，采用多激酶抑制剂，靶向血管內皮生长因子受体及血小板衍 生生长因子受体，适用于治疗血管化睑裂斑。是次第2期临床试验后会议是CBT-004研发进程中一个重 要的里程碑，用于讨论CBT-004研发进程中潜在的第三阶段临床试验开发以及新药申请的相关要求。 ...

CBT-004是一种潜在的同类首创眼科药物，采用多激酶抑制剂，靶向血管内皮生长因子受体及血小板衍 生生长因子受体，适用于治疗血管化睑裂斑。本集团于2023年12月开始CBT-004的第2期临床试验，并 于2025年5月完成。结果表明，CBT-004 在受试者中是安全且耐受性良好的，并在疗效方面达到了主要 终点以及若干次要终点。本集团已于2025年7月完成临床试验报告并计划与美国食品及药物管理局举行 第2期临床试验后会议。 是次第2期临床试验后会议是CBT-004研发进程中一个重要的里程碑，用于讨论CBT-004研发进程中潜在 的第三阶段临床试验开发以及新药申请的相关要求。本公司将适时发布进一步公告，以确保本公司股东 及潜在投资者能及时掌握本集团业务的最新进展。 拨康视云-B(02592)发布公告，本公司于美利坚合众国(美国)加利福尼亚州注册成立的全资附属公司 Cloudbreak Therapeutics LLC(Cloudbreak USA)排定于2025年12月10日与美国食品及药物管理局(美国食 品及药物管理局)正式举行第2期临床试验后会议，该会议涉及本集团临床阶段候选药物 CBT-004。 诚如本公司 ...

CBT-004是一种潜在的同类首创眼科药物，采用多激酶抑制剂，靶向血管内皮生长因子受体及血小板衍 生生长因子受体，适用于治疗血管化睑裂斑。本集团于2023年12月开始CBT-004的第2期临床试验，并 于2025年5月完成。结果表明，CBT-004 在受试者中是安全且耐受性良好的，并在疗效方面达到了主要 终点以及若干次要终点。本集团已于2025年7月完成临床试验报告并计划与美国食品及药物管理局举行 第2期临床试验后会议。 诚如本公司于日期为2025年6月24日的招股章程及本集团截至2025年6月30日止六个月的中期报告所披 露: 智通财经APP讯，拨康视云-B(02592)发布公告，本公司于美利坚合众国(美国)加利福尼亚州注册成立的 全资附属公司Cloudbreak Therapeutics LLC(Cloudbreak USA)排定于2025年12月10日与美国食品及药物管 理局(美国食品及药物管理局)正式举行第2期临床试验后会议，该会议涉及本集团临床阶段候选药物 CBT-004。 是次第2期临床试验后会议是CBT-004研发进程中一个重要的里程碑，用于讨论CBT-004研发进程中潜在 的第三阶段临床试验开 ...

CBT-004是一种潜在的同类首创眼科药物，采用多激酶抑制剂，靶向血管内皮生长因子受体及血小板衍 生生长因子受体，适用于治疗血管化睑裂斑。集团于2023年12月开始CBT-004的第2期临床试验，并于 2025年5月完成。结果表明，CBT-004 在受试者中是安全且耐受性良好的，并在疗效方面达到了主要终 点以及若干次要终点。集团已于2025年7月完成临床试验报告并计划与美国食品及药物管理局举行第2期 临床试验后会议。 格隆汇12月8日丨拨康视云-B(02592.HK)宣布，公司于美国加利福尼亚州注册成立的全资附属公司 Cloudbreak USA排定于 2025 年 12 月 10日与美国食品及药物管理局正式举行第2期临床试验后(「第2期 临床试验后」)会议，该会议涉及集团临床阶段候选药物 CBT-004。 是次第2期临床试验后会议是CBT-004研发进程中一个重要的里程碑，用于讨论CBT-004研发进程中潜在 的第三阶段临床试验开发以及新药申请的相关要求。 ...

Core Viewpoint - The successful patent grants for CBT-009 represent a significant milestone in the product's development, enhancing its global reach and commercial potential [1][3]. Group 1: Patent Achievements - ADS Therapeutics LLC, a wholly-owned subsidiary of the company, has been granted patents in Japan and Europe for CBT-009, which involves various ophthalmic compositions aimed at treating myopia [1]. - The Japanese patent (No. 7749020) was issued on September 25, 2025, and published on October 3, 2025, covering non-aqueous ophthalmic compositions containing specific amounts of atropine and other compounds [1]. - The European patent (No. 4225284) was granted on November 26, 2025, and published on the same day, also focusing on ophthalmic compositions for treating myopia [1]. Group 2: Product Development - CBT-009 is a novel atropine ophthalmic formulation designed for treating myopia in children and adolescents aged 5 to 19, offering improved stability, safety, and patient tolerance compared to existing aqueous formulations [2]. - The combined Phase 1 and Phase 2 clinical trials for CBT-009 were completed in Australia in January 2023, demonstrating good safety and efficacy [2]. - The company received a non-objection letter from the FDA in September 2024, allowing the initiation of Phase 3 clinical trials after a six-month ocular toxicity study [2]. Group 3: Commercialization Potential - The successful patent applications are expected to facilitate collaborations with major pharmaceutical companies for the production, development, and distribution of CBT-009 in key markets like Japan and Europe [3]. - These collaborations and licensing arrangements are anticipated to enhance and accelerate the global commercialization potential of CBT-009 [3].

Core Viewpoint - The successful patent grants for CBT-009 represent a significant milestone in the product's development, enhancing its global reach and commercial potential [1][3]. Group 1: Patent Achievements - ADS Therapeutics LLC has been granted patents in Japan and Europe for CBT-009, which involves non-aqueous ophthalmic compositions aimed at treating myopia [1]. - The Japanese patent (No. 7749020) was issued on September 25, 2025, and published on October 3, 2025, covering various ophthalmic compositions including atropine and specific compounds [1]. - The European patent (No. 4225284) was granted on November 26, 2025, and published the same day, also focusing on compositions for treating myopia [1]. Group 2: Product Development - CBT-009 is a novel atropine ophthalmic formulation designed for treating myopia in children and adolescents aged 5 to 19, offering improved stability, safety, and patient tolerance compared to existing aqueous formulations [2]. - Preclinical studies for CBT-009 began in China and the U.S. in 2021 and 2022, respectively, with combined Phase 1 and 2 clinical trials completed in Australia in January 2023, demonstrating good safety and efficacy [2]. - The company received a non-objection letter from the FDA in September 2024, allowing for the initiation of Phase 3 clinical trials, with ongoing preparations for these trials in China [2]. Group 3: Commercialization Potential - The successful patent applications are expected to facilitate collaborations with major pharmaceutical companies for the production, development, and distribution of CBT-009 in key markets like Japan and Europe [3]. - These collaborations and licensing arrangements are anticipated to enhance and accelerate the global commercialization potential of CBT-009 [3].